Patent · US Active

Engineered CRISPR-Cas9 nucleases

US9512446B1 · kind B1 · utility

128Cited by

24References

27Claims

0Family size

Assignee

The General Hospital Corporation · US

Inventors

J. Keith Joung · Winchester, US
Benjamin Kleinstiver · Medford, US
Vikram Pattanayak · Wellesley, US

Key dates

Filing date	Feb 4, 2016
Grant date	Dec 6, 2016
Priority date	—
Expiry date	Feb 4, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/22
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.